Voxar launches calcium scoring package
An advanced calcium scoring application developed by the Scottish firm Voxar has cleared the FDA. Voxar Calscreen 2.1 is designed to detect, quantify, and report the presence of calcium plaque in the coronary arteries. It complements the company's
An advanced calcium scoring application developed by the Scottish firm Voxar has cleared the FDA. Voxar Calscreen 2.1 is designed to detect, quantify, and report the presence of calcium plaque in the coronary arteries. It complements the company's flagship Plug n View 3D and Voxar Colonscreen products. The package automates the identification of calcified plaques in the coronary arteries and calculates the calcium score, providing the basis for assessing potential risk and managing associated coronary heart disease before symptoms arise. Calscreen 2.1 works with electron-beam tomography scanners and multislice or helical CTs. The package, which runs on a standard PC, automatically highlights calcified regions in red as part of multiplanar reformatted (MPR) and 3D views of the heart.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study with CT Data Suggests Women with PE Have More Than Triple the One-Year Mortality Rate than Men
April 3rd 2025After a multivariable assessment including age and comorbidities, women with pulmonary embolism (PE) had a 48 percent higher risk of one-year mortality than men with PE, according to a new study involving over 33,000 patients.
